Repair Biotechnologies is a late preclinical-stage biotech company developing several first-in-class therapies based on the Cholesterol Degrading Platform (CDP)
Our company started with ambitious goals.
CDP is an innovative platform and can be applied to many different indications that involve excess cholesterol in their pathology. These include multi-billion dollar markets with high unmet need, such as atherosclerosis, as well as orphan conditions such as homozygous familial hypercholesterolemia.
Repair Biotechnologies has at present strong preclinical evidence in cells and animal models for the efficacy of CDP therapy. We have a clear path ahead to become a platform company with multiple approved therapies.